Gate News bot message, according to the official Gate announcement: Gate has delisted trading markets for 38 tokens, including RUNECOIN, SHARE, WUF, BUBB, SN, SAKAI, TAP, CROS, MIS, FINE, INTR, BLOCKASSET, TALK, NOTAI, BSCPAD, OCT, GQ, EGP, YFDAI, DNOW, ANDR, MBS, AKV, NFTD, DOGE2, PSY, BAKED, YULI, BEES, MEMUSIC, VDA, AIEPK, BLS, MOVEZ, STZ, LEMD, STAGE, KIM, among others. The related trading pairs have been removed from the platform. Gate states that it has conducted buybacks of the relevant tokens stored on the platform, and the buyback amounts for eligible users have been credited to their Gate accounts. After delisting, users can still use Gate as a wallet for these tokens to store assets. The specific delisting time for wallet functions will be announced separately through future official notices.

Gate News bot message, according to the official Gate announcement Gate has re-evaluated and decided to delist trading markets for 38 tokens. The tokens involved in the delisting include RUNECOIN, SHARE, WUF, BUBB, SN, SAKAI, TAP, CROS, MIS, FINE, INTR, BLOCKASSET, TALK, NOTAI, BSCPAD, OCT, GQ, EGP, YFDAI, DNOW, ANDR, MBS, AKV, NFTD, DOGE2, PSY, BAKED, YULI, BEES, MEMUSIC, VDA, AIEPK, BLS, MOVEZ, STZ, LEMD, STAGE, KIM, etc., and the related spot trading pairs and quantitative grid will be delisted simultaneously. Gate has suspended deposits for these tokens and will suspend trading services at 11:00 on February 2, 2026 (UTC+8). Users holding positions can choose to withdraw their tokens or transfer them to Gate Web3 Wallet for permanent storage. After February 16, 2026, users with token holdings still stored on Gate can apply for buyback within the specified time. Gate will buy back at the designated price, with a maximum compensation limit of 100 USDT per user. Among them, LEMD tokens are temporarily unable to contact the project team due to on-chain anomalies and do not support withdrawal services on this chain for now. The service will be restored immediately once the issue is resolved.

Jinshi data news on October 7th, Notai Biology released performance forecast, it is expected that the net profit attributable to the owner of the parent company in the third quarter of 2024 will be 100 million to 140 million, an increase of 100.56% to 180.78% year-on-year. During the reporting period, the sales revenue of the company's polypeptide bulk drugs increased significantly compared to the same period last year.

🔥 #GateioStartup Voting Event 6th Round Vote for your next hot project and share the $5000 prize pool in your mind👇 https://gate.io/activities/startupvote?gt_disable_intercept_jump=1&now_period=7 Project list: MATRIX, CRS, AGENT, OCTA, BASEX, DEAI, BOX, MAO, USBT, CATEETH, NOTAI, AIRDROP ⏳Deadline: September 19th 14:00 (UTC+8) 📖 Learn more: https://gate.io/announcements/article/39201